Obinutuzumab‐Based Drug‐Free Macromolecular Therapeutics Synergizes with Topoisomerase Inhibitors

Drug‐free macromolecular therapeutics (DFMT) utilizes modified monoclonal antibodies (or antibody fragments) to generate antigen‐crosslinking‐induced apoptosis in target cells. DFMT is a two‐component system containing a morpholino oligonucleotide (MORF1) modified antibody (Ab‐MORF1) and human serum...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Macromolecular bioscience 2024-03, Vol.24 (3), p.e2300375-n/a
Hauptverfasser:	Gambles, M. Tommy, Sborov, Douglas, Shami, Paul, Yang, Jiyuan, Kopeček, Jindřich
Format:	Artikel
Sprache:	eng
Schlagworte:	Alkylating agents Alkylation Animals Antagonism Antibodies, Monoclonal, Humanized - pharmacology Antigens, CD20 - genetics Antineoplastic Agents Apoptosis Calcium (mitochondrial) Calcium influx Calcium ions CD20 antigen CD20 crosslinking Cell cycle Cell surface chemo‐immunotherapy Combinations (mathematics) Combinatorial analysis Complementation Crosslinking Deoxyribonucleic acid DNA DNA biosynthesis DNA topoisomerase inhibitors drug‐free macromolecular therapeutics Etoposide Human serum albumin Humans Inhibitors Lymphoma Macromolecular Substances Macromolecules Mice Monoclonal antibodies Morpholinos Non-Hodgkin's lymphoma Nucleotide analogs Nucleotides obinutuzumab Oligonucleotides Serum albumin Synergism Topoisomerase Inhibitors Xenotransplantation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!